About: Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity
Creator	Jang, Sun-Hee Jang, Yong-Suk Kim, Ju Yang, Ye
Source	Medline; PMC
abstract	BACKGROUND: Antimicrobial peptides (AMPs) are primarily known for their innate immune defense against invading microorganisms, including viruses. In addition, recent research has suggested their modulatory activity in immune induction. Given that most subunit vaccines require an adjuvant to achieve effective immune induction through the activation of innate immunity, AMPs are plausible candidate molecules for stimulating not only innate immune but also adaptive immune responses. RESULTS: In this study, we investigated the ability of human β-defensin (HBD) 2 to promote antiviral immunity in vitro and in vivo using a receptor-binding domain (RBD) of Middle East respiratory syndrome-coronavirus (MERS-CoV) spike protein (S RBD) as a model antigen (Ag). When HBD 2-conjugated S RBD was used to treat THP-1 human monocytic cells, the expression levels of antiviral (IFN-β, IFN-γ, MxA, PKR, and RNaseL) and primary immune-inducing (NOD2, TNF-α, IL-1β, and IL-6) molecules were enhanced compared to those expressed after treatment with S RBD only. The expression of chemokines capable of recruiting leukocytes, including monocytes/macrophages, natural killer cells, granulocytes, T cells, and dendritic cells, was also increased following HBD 2-conjugated S RBD treatment. More important, immunization of mice with HBD 2-conjugated S RBD enhanced the immunogenicity of the S RBD and elicited a higher S RBD-specific neutralizing antibody response than S RBD alone. CONCLUSIONS: We conclude that HBD 2 activates the primary antiviral innate immune response and may also mediate the induction of an effective adaptive immune response against a conjugated Ag.
has issue date	2018-08-08(xsd:dateTime)
bibo:doi	10.1186/s12985-018-1035-2
bibo:pmid	30089512
has license	cc-by
sha1sum (hex)	5cc7d19d8c064e59978daa0699ca18d5b139b0db
schema:url	https://doi.org/10.1186/s12985-018-1035-2
resource representing a document's title	Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity
has PubMed Central identifier	PMC6083524
has PubMed identifier	30089512
schema:publication	Virol J
resource representing a document's body	covid:5cc7d19d8c064e59978daa0699ca18d5b139b0db#body_text
is schema:about of	named entity 'REGULATORY ROLE' named entity 'HBD' named entity 'immunity' named entity 'antiviral' named entity 'addition' named entity 'immunity' named entity 'HUMAN' named entity 'IMMUNITY' named entity 'IN VITRO' named entity 'CORONAVIRUS' named entity 'DEFENSE' named entity 'GIVEN' named entity 'RECRUITING' named entity 'IMMUNE INDUCTION' named entity 'IMMUNITY' named entity 'RNASEL' named entity 'ELICITED' named entity 'DENDRITIC CELLS' named entity 'RESULTS' named entity 'AFTER TREATMENT' named entity 'IN VIVO' named entity 'DEFENSIN' named entity 'PKR' named entity 'RECENT' named entity 'ADDITION' named entity 'HUMAN' named entity 'RESEARCH' named entity 'MOLECULES' named entity 'PROMOTE' named entity 'IL-1' named entity '28S' named entity 'PRIMARY' named entity 'THEIR' named entity 'ANTIVIRAL' named entity 'SPECIFIC IMMUNITY' named entity 'IMMUNIZATION' named entity 'CANDIDATE' named entity 'PROTEIN ' named entity 'INDUCTION' named entity 'ANTIGEN' named entity 'SPECIFIC' named entity 'SUBUNIT VACCINES' named entity 'BINDING' named entity 'PEPTIDES' named entity 'T CELLS' named entity 'USED' named entity 'INCREASED' named entity 'ANTIMICROBIAL' named entity 'MXA' named entity 'IMMUNE' named entity 'ANTIGEN' named entity 'INCLUDING' named entity 'RBD' named entity 'NATURAL KILLER CELLS' named entity 'RECEPTOR' named entity 'CELLS' named entity 'IMMUNOGENICITY' named entity 'VIRUSES' named entity 'ADAPTIVE IMMUNE RESPONSES' named entity 'MICE' named entity 'INVESTIGATED' named entity 'ENHANCED' named entity 'GRANULOCYTES' named entity 'EXPRESSED' named entity 'NEUTRALIZING ANTIBODY' named entity 'KNOWN' named entity 'LEVELS' named entity 'CAPABLE' named entity 'ACTIVATION' named entity 'INNATE IMMUNITY' named entity 'MONOCYTIC' named entity 'LEUKOCYTES' named entity 'COMPARED' named entity 'STIMULATING' named entity 'FOLLOWING' named entity 'CHEMOKINES' named entity 'CONJUGATED' named entity 'INDUCING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software